Skip to content

CEO and Business

Luiz Carlos Trabuco And His Lengthy, Respectable Career

Luiz Carlos Trabuco is the President and Chief Executive Officer of Banco Bradesco, a large bank in Brazil that’s only second to one other financial institution – Itaú Unibanco, formed by one of the largest mergers in Brazilian history 9 years ago.

Most people know Luiz Carlos Trabuco from headlines in 2015 along the lines of “Bradesco CEO Trabuco Pushes for Purchase of HSBC Brazil.” The transaction was expensive, weighing in at 5.2 billion United States Dollars. Trabuco noted to the press that he first thought about purchasing HSBC Brazil’s banking locations in late 2014, although not everybody within Bradesco’s ranks were in favor of the transaction. After a few months of convincing everyone as best he could – couldn’t have been too difficult with his postgraduate Socio-Psychology degree – the deal was approved by Chairman of Bradesco’s Board, Lázaro Brandão.

Mr. Brandão used to be the President, and was the first to hold the top executory role after the original founder, Amador Aguiar, stepped down in 1981, citing his failing health.

Luiz Carlos Trabuco experienced success in the banking industry by working for the same financial institution for a long period of time, as well as equipping himself with two relevant, helpful degrees.

Mr. Trabuco kicked his career off by attending the University of São Paulo, quickly earning a bachelor’s degree from the Faculty of Philosophy, Letters, and Human Sciences at the University of São Paulo. Going to USP, shorthand for the University of São Paulo, was unarguably beneficial for Luiz Carlos Trabuco, as it’s consistently rated one of the top universities in Brazil, not to mention the entire continent of South America.

Like Luis Carlos Trabuco on Facebook

Immediately after graduating from USP, he stayed within Brazil’s largest state of São Paulo and went to the Foundation School of Sociology and Politics of São Paulo in earning a master’s degree in Sociopsychology, unarguably helping Mr. Trabuco effectively communicate with others within Bradesco’s ranks, resulting in an all-around better, more fruitful career in the ever-competitive banking industry.

After getting his hands on these two degrees, Mr. Luiz Carlos Trabuco then traveled hundreds of miles back to his hometown of Marília, shortly after beginning his first “big boy” job as a bank teller and clerk at Banco Bradesco’s very first branch, although they had dozens, if not hundreds of branches of the bank spread across the nation of Brazil in 1969, the year in which Luiz Carlos Trabuco joined forces with Bradesco. Two years later, in 1971, Bradesco had some important news for Luiz Carlos Trabuco – they wanted him to fill an entry-level spot at their headquarters. However, it would require Mr. Trabuco to move another five hours or better across Brazil’s stateside, for at least the second time in two years, if not more often.

Without any hesitation whatsoever, Luiz Carlos Trabuco sped across Brazil to join Banco Bradesco and its headquarters nestled away in the metropolitan São Paulo, São Paulo, more specifically the Cidade de Deus inside of Osasco. It was here where Mr. Trabuco would spend the entirety of his working life, still yet to end as of September of 2017.

Mr. Luiz Carlos Trabuco moved up to the rank of Director of Marketing within Bradesco’s ranks in 1984, remaining there for eight years until being shipped to the bank’s pension management company. In 1992, he was known as the Executive Director, then in 1998, President became his title. It was just one year after becoming the supreme leader of Bradesco’s insurance subsidiary – 1999 Luiz Carlos Trabuco was crowned the Executive Vice Chairman, then in 2003, not long thereafter, he earned another title of President.

Mr. Trabuco became President of Bradesco in its entirety, having done great things in his 8-year tenure.

Learn more about Luis Carlos Trabuco: https://br.investing.com/news/mercado-de-a%C3%A7%C3%B5es-e-financeiro/bradesco-retomada-de-credito-a-partir-do-fim-de-2017-diz-trabuco-508466

Timothy Armour Shares his Professional View on Active Investing

Warren Buffett had made a $1 million better with a number of hedge fund managers that he could beat them all over a long period by putting his $1 million into a passive fund that followed the companies that make up the S&P 500. With the end of the contest in sight, it’s pretty clear that Buffett is going to win his bet and more information click here.

 

Financial industry expert Timothy Armour fully agrees with Buffett that way too many actively managed funds have too high of fees and mediocre returns. However, he doesn’t agree that well managed active funds can’t do better than a passive one, rather the investor needs to do more research to find the good one. Timothy Armour says that there are active funds that feature low fees and market-beating returns and more information click here.

 

As to how to find a great active fund to invest in, Timothy Armour advises finding ones that the fund manager is confident enough in to put their own money into it. These funds have managers who can consistently beat their peers in the industry and are well worth seeking out. This is especially the case when markets enter bear territory as a good manager can mitigate losses during these times while a passive S&P 500 fund will collapse in value with the rest of the stock market and learn more about Timothy.

 

Timothy Armour has over 30 years of financial market experience. He is the Chairman of the Board of Capital Group of Companies, Inc., a financial services firm located in Los Angeles, California. Armour is also an Equity Portfolio Manager and still manages a number of active funds. He first joined Capital Group in 1983 and quickly advanced to a position as an Equity Investment Analyst. During the time he was in this position he specialized in service companies located in the United States as well as in telecommunications companies located around the world.

 

More visit: https://medium.com/@timarmour

Jason Hope has Keen Sense of where Things are Heading

Jason Hope is Arizona’s most famous internet entrepreneur. Known for starting premium mobile content provider Jawa, Hope has gone on to found a string of ultra-successful internet companies. Among these are SEO agencies, brand consulting firms, app developers and internet marketing solutions.

 

This long track record of stellar achievement has made Hope one of the keenest observers of the technology sector. Today, Hope is considered one of the nation’s foremost experts on technological trends and understanding the implications future technologies on individuals and society as a whole.

 

For this reason, Hope has taken to the internet, writing for various news outlets, blogs and tech websites. One of the things that Hope sees as a potentially radically disruptive technology is the upcoming advent of The Internet of Things. Hope believes that the Internet of Things will have benefits for everyone’s lives. This will represent one of the most radically transformative shifts in daily-use technology that people have seen since the invention of the automobile.

 

In fact, Hope Jason believes that the automobile itself will be radically transformed by the Internet of Things and related technologies. One way in which Hope sees cars being transformed by modern inventions are the use and widespread implementation of self-driving automobiles. Hope believes that within five to ten years, this technology will be widespread and will hugely increase the productivity and efficiency of everyday Americans.

 

Hope believes that self-driving cars will virtually eliminate traffic accidents and will dramatically increase the amount of productive time that people are able to enjoy as a result of not being required to drive and learn more about Jason.

 

More visit: http://finance.yahoo.com/news/jason-hope-explores-internet-things-090000898.html

Jeffrey Schneider – Founder and CEO of Ascendant Capital

Jeffry Schneider is the founder and chief executive of Ascendant Capital. He founded this company back in March 2012. He is a creative, dedicated and result-oriented man. Jeffry Schneider has acquired the skills of alternative investment ideas and analysis of managers to run his 5 year company with huge successes. Ascendant Capital is an alternative investment outfit that raises money for sponsors of alternative investments. It works with banks, brokerage firms and family offices. Alternative investment is the new way to raise a company’s capital base.

Under Jeffry’s auspices, Ascendant Capital has been able to raise close to $1 billion for its clients. The company now has an ambitious goal of raising an average of $50 million every month. With Jeffrey on top, the goal can be achieved. He holds a Bachelor’s of Science Degree from the University of Massachusetts Amherst. He has put to use his skills previously at Axiom Capital Management since March 2002 till May 2004 after which he did the same at Paradigm Global Advisors till January 2006.

Apart from having investment skills, Jeffrey is also a fitness enthusiast. He attends the iron man, half iron mans and marathons. He also likes to travel and has toured Europe, Asia and South America. He hails from Manhattan and now resides at Austin, Texas. He is passionate about charitable work and is working with organizations such as the Gazelle Foundation. He has also previously worked for Alex Brown, Merrill Lynch and Smith Barney.In conclusion, Jeffrey Schneider is an alternative investment kingpin who prides himself in founding and successfully leading Ascendant Capital LLC to success. He also loves charitable work. He originally comes from Manhattan but now resides in Austin Texas.

More visit: http://jeffryschneider.org/

Seattle Genetics Embarks On A Plan To Expand Its Services

After Joe Biden visited the corporation, Seattle Genetics is enjoying the limelight. The Bothell-based cancer drug company has embarked on a plan to expand its services through production of 12 new drugs. It also plans to enlarge its staff by employing 100 new employees. Being a center for cancer research, the plan reflects Seattle Genetics’ mission to improve healthcare, especially on cancer treatment. According to Clay Siegall, Seattle Genetics’ chief executive officer, Adcetris, the only commercialized drug manufactured by Seattle Genetics is in the trial stage.

In addition, the company is embarking on a more advanced clinical trial where Adcetris will be used as a major treatment for Hodgkin lymphoma that was previously treated or newly diagnosed. In 2015, Adcetris, which is mostly used to fight lymphoma, racked up sales of $226 million in the United States and Canada. While addressing the investors, the company officials said that they were anticipating the numbers to shoot up to between $255 and $275 million this year, in the same countries. Seattle Genetics partners with Takeda Pharmaceutical, a company that sells Adcetris drug outside the two countries.

Among the 12 new drugs being developed, Seattle Genetics plans to use a drug called 33A to treat acute myeloid leukemia in phase three of the clinic trials. The company has also developed a drug for breast cancer and other two for bladder cancer. As they focus on expanding its drug pipeline, Seattle Genetics is embarking on a hiring exercise where it plans to hire 100 workers in the U.S. and approximately 20 for the Switzerland office. Siegall said that the company already has over 800 staff members. This information was originally reported on Bizjournals.

About Clay Siegall
The CEO and president of Seattle Genetics co-founded the company in 1998. He chairs the board of directors. Siegall is an alumnus of the prestigious University of Maryland and the esteemed George Washington University. From these institutions, he graduated with a B.S. in Zoology and earned a PhD. in Genetics respectively. Mr. Siegall is an author and holds 15 patents. Clay B. Siegall has worked with several companies, including Bristol-Myers Squibb Pharmaceutical Research Institute, National Institutes of Health, and National Cancer institute. As a board member, he is heavily involved in the operations of Mirna Therapeuticals and Alder BioPharmaceuticals. This information was originally published on Ultragenyx’s website.